S95031
Payments companies reported to CMS as associated with S95031. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with S95031, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with S95031
These are the largest totals companies reported as associated with S95031. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Philippos Apolinario Costa | New Haven, CT | Medical Oncology | $64.84 |
| Christian Meyer | Baltimore, MD | Medical Oncology | $64.84 |
| William Tap | New York, NY | Hematology & Oncology | $64.84 |
| Benjamin Nacev | New York, NY | Medical Oncology | $64.84 |
| Jonathan Trent | Miami, FL | Medical Oncology | $64.84 |
| Anthony Conley | Houston, TX | Medical Oncology | $64.84 |
| Gabriel Tinoco Suarez | Columbus, OH | Medical Oncology | $64.84 |
| Richard Riedel | Durham, NC | Internal Medicine | $64.84 |
| James Harding | New York, NY | Hematology & Oncology | $50.00 |
| Richard Kim | Tampa, FL | Hematology & Oncology | $50.00 |
Prescribed S95031?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.